Linclatamig Biosimilar Bispecific Antibody (LY6G6D × CD3) for Research

Cat No.: GMP-Bios-INN-1259

Anti-LY6G6D/G6D/NG25/LY6-D/MEGT1/C6orf23 therapeutic antibody (Pre-made Linclatamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Linclatamig (development codes BLYG-8824A/RG6286) is a bispecific antibody targeting LY6G6D and CD3. It is developed by Genentech for solid tumors. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1259-1mg 1mg
GMP-Bios-INN-1259-10mg 10mg
GMP-Bios-INN-1259-100mg 100mg
GMP-Bios-INN-1259-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Linclatamig biosimilar, Bispecific mAb, Anti-LY6G6D/G6D/NG25/LY6-D/MEGT1/C6orf23;CD3E Antibody: Anti-LY6G6D/Lymphocyte antigen 6 complex locus protein G6d/Protein Ly6-D/Megakaryocyte-enhanced gene transcript 1 protein therapeutic antibody
INN Name Linclatamig
Target LY6G6D/G6D/NG25/LY6-D/MEGT1/C6orf23;CD3E
Format Bispecific mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Discontinued
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended 2024
Companies Genentech
Conditions Approved na
Conditions Active na
Conditions Discontinued Metastatic colorectal cancer
Production na
Development Tech na